ES2216049T3 - Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos. - Google Patents

Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos.

Info

Publication number
ES2216049T3
ES2216049T3 ES96922490T ES96922490T ES2216049T3 ES 2216049 T3 ES2216049 T3 ES 2216049T3 ES 96922490 T ES96922490 T ES 96922490T ES 96922490 T ES96922490 T ES 96922490T ES 2216049 T3 ES2216049 T3 ES 2216049T3
Authority
ES
Spain
Prior art keywords
compound
nhe
cells
growth
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96922490T
Other languages
English (en)
Spanish (es)
Inventor
Michael Zasloff
Ann Shinnar
William A. Kinney
Jon Williams
Meena N. Rao
Mark Anderson
Michael Mclane
Steven Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genaera Corp
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/475,572 external-priority patent/US5840936A/en
Priority claimed from US08/487,443 external-priority patent/US5847172A/en
Priority claimed from US08/483,057 external-priority patent/US5795885A/en
Priority claimed from US08/479,457 external-priority patent/US5763430A/en
Priority claimed from US08/476,855 external-priority patent/US5874597A/en
Priority claimed from US08/483,059 external-priority patent/US5840740A/en
Priority claimed from US08/479,455 external-priority patent/US5994336A/en
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of ES2216049T3 publication Critical patent/ES2216049T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
ES96922490T 1995-06-07 1996-06-07 Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos. Expired - Lifetime ES2216049T3 (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US475572 1995-06-07
US476855 1995-06-07
US08/475,572 US5840936A (en) 1995-06-07 1995-06-07 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US08/487,443 US5847172A (en) 1995-06-07 1995-06-07 Certain aminosterol compounds and pharmaceutical compositions including these compounds
US08/483,057 US5795885A (en) 1995-06-07 1995-06-07 Method of inhibiting profileration of cells by administering an aminosterol compound
US08/479,457 US5763430A (en) 1995-06-07 1995-06-07 Method of treating a viral infection by administering a steroid compound
US483059 1995-06-07
US479455 1995-06-07
US487443 1995-06-07
US08/476,855 US5874597A (en) 1995-06-07 1995-06-07 Certain aminosterol compounds and pharmaceutical compositions including these compounds
US483057 1995-06-07
US08/483,059 US5840740A (en) 1995-06-07 1995-06-07 Aminosterol compounds and a method of treating infection using the aminosterol compounds
US479457 1995-06-07
US08/479,455 US5994336A (en) 1995-06-07 1995-06-07 Method of inhibiting proliferation of cells by administering an aminosterol compound
PCT/US1996/010508 WO1996040728A2 (en) 1995-06-07 1996-06-07 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds

Publications (1)

Publication Number Publication Date
ES2216049T3 true ES2216049T3 (es) 2004-10-16

Family

ID=27569803

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96922490T Expired - Lifetime ES2216049T3 (es) 1995-06-07 1996-06-07 Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos.

Country Status (10)

Country Link
EP (2) EP0832094B1 (https=)
JP (2) JP4104164B2 (https=)
AT (1) ATE259375T1 (https=)
AU (1) AU723663C (https=)
CA (1) CA2223910C (https=)
DE (1) DE69631527T2 (https=)
DK (1) DK0832094T3 (https=)
ES (1) ES2216049T3 (https=)
PT (1) PT832094E (https=)
WO (1) WO1996040728A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
ES2201296T3 (es) * 1996-04-26 2004-03-16 Genaera Corporation Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
EP0923377A1 (en) * 1996-05-17 1999-06-23 Magainin Pharmaceuticals Inc. Therapeutic uses for an aminosterol compound
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
AU5194998A (en) * 1996-11-01 1998-05-29 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and uses therefor
US6262283B1 (en) * 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
PT1274718E (pt) 2000-04-12 2007-01-31 Genaera Corp Processo para a preparação de esteróis 7. alfa-hidroxi 3- aminosubstítuidos utilizando intermediários com um grupo 7. alfa-hidroxilo desprotegido
WO2006119211A2 (en) * 2005-05-02 2006-11-09 Genaera Corporation Methods and compositions for treating ocular disorders
US20080058300A1 (en) * 2006-04-21 2008-03-06 Mclane Michael Induction of weight loss and the selective inhibition of PTP1B
JP2010538072A (ja) * 2007-09-06 2010-12-09 ジェナエラ コーポレイション 糖尿病を治療する方法
AU2009243749B2 (en) * 2008-05-09 2013-11-21 Merck Patent Gmbh Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction
BR112014003704A2 (pt) * 2011-09-19 2017-03-07 Eth Zuerich moduladores ror gama
ES2736310T3 (es) * 2012-04-20 2019-12-27 Ohr Pharmaceutical Inc Aminoesteroides para el tratamiento de una enfermedad asociada a PTP1B
WO2014151411A1 (en) 2013-03-15 2014-09-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
US10441595B2 (en) * 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
FR3033563B1 (fr) * 2015-03-12 2018-04-13 Virbac Composes analogues de la squalamine utiles comme agents antibacteriens
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
MA50094A (fr) * 2017-09-08 2020-07-15 Enterin Inc Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
WO2021025974A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same
EP4007764B1 (en) 2019-08-02 2026-01-21 Enterin, Inc. Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
CN112782300B (zh) * 2020-12-25 2022-04-12 山东省食品药品检验研究院 一种胆烷酸的同分异构体及其检测方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) * 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
WO1994019366A1 (en) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
DE69412596T2 (de) * 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel

Also Published As

Publication number Publication date
CA2223910A1 (en) 1996-12-19
EP0832094A2 (en) 1998-04-01
ATE259375T1 (de) 2004-02-15
JP2007314577A (ja) 2007-12-06
AU723663C (en) 2001-11-01
DK0832094T3 (da) 2004-05-17
CA2223910C (en) 2008-09-16
PT832094E (pt) 2004-06-30
WO1996040728A3 (en) 1997-03-27
EP1420027A2 (en) 2004-05-19
EP0832094B1 (en) 2004-02-11
JP2002515019A (ja) 2002-05-21
AU6334996A (en) 1996-12-30
JP4104164B2 (ja) 2008-06-18
AU723663B2 (en) 2000-08-31
EP1420027A3 (en) 2012-01-04
WO1996040728A2 (en) 1996-12-19
DE69631527D1 (de) 2004-03-18
DE69631527T2 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
ES2216049T3 (es) Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos.
ES2201187T3 (es) Uso de la escualamina para la fabricacion de un medicamento para inhibir el nhe.
US5763430A (en) Method of treating a viral infection by administering a steroid compound
US20060183928A1 (en) Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds
CN102548560B (zh) 用于预防和治疗冠心病的组合物和方法
McCully et al. Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury
CN105395532B (zh) 2‑苯磺酰胺基苯甲酰胺类化合物在肝损伤保护和肝纤维化防治中的应用
US5840936A (en) Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5795885A (en) Method of inhibiting profileration of cells by administering an aminosterol compound
EA023864B1 (ru) Применение мацитентана в комбинации с цитотоксическим химиотерапевтическим средством и/или лучевой терапией для лечения метастазов в головном мозге
Bibby et al. Flavone acetic acid—from laboratory to clinic and back
US5840740A (en) Aminosterol compounds and a method of treating infection using the aminosterol compounds
US20240238271A1 (en) Pharmaceutical composition for enhancing cell killing, and use thereof
CN112891340A (zh) Pso用于制备治疗蒽环类化疗药物诱发的心脏毒性药物的应用
Xian-mei et al. Study on the effect of doxorubicin on expressions of genes encoding myocardial sarcoplasmic reticulum Ca2+ transport proteins and the effect of taurine on myocardial protection in rabbits
JP2020508290A (ja) ゴシポールおよびフェンホルミンを有効成分として含む膵臓癌予防および治療用薬学的組成物
KR102562739B1 (ko) 암의 기원 세포의 사멸용 약학적 조성물
US5874597A (en) Certain aminosterol compounds and pharmaceutical compositions including these compounds
US6451846B1 (en) Isocoumarin derivatives inhibiting angiogenesis
KR101629558B1 (ko) 나프탈렌계 칼콘 및 그의 항암제로서의 용도
WO2007122280A1 (es) Uso del factor de crecimiento de hígado (lgf) como regenerador tisular pleiotrópico
CN117736251A (zh) 一类香豆素苷及其制备方法和其药物组合物与用途
CN107334765A (zh) 一种治疗癌症的药物组合物及其用途
WO1999034795A1 (en) Neovascularization inhibitors